Vancomycin Injectable Solution Recalled Due to Sterility Assurance Concerns Nationwide
Central Admixture Pharmacy Services is recalling 3,075 bags of vancomycin injectable solution nationwide due to lack of assurance of sterility following an FDA inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries and a theoretical hazard (lack of sterility assurance rather than confirmed contamination), which per the rubric means the score is at most 3. This qualifies as a risk-of-harm product (sterile injectable) where injury has not yet been reported, placing it at the High (3) level.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling vancomycin added to 0.9% sodium chloride solution (750 mg/250 mL concentration, 250 mL per bag, NDC 71285-6071-1) nationwide. The recall affects 3,075 bags with specific lot numbers and expiration dates ranging from May 3, 2023 to June 14, 2023.
The recall was initiated following an FDA inspection that determined there was insufficient assurance of sterility for these products, which are manufactured as sterile injectables intended for intravenous use. Non-sterile injectables may pose a risk of serious infection to patients.
The product was distributed nationwide in the United States.
The recalled product
- Product
- vancomycin added to 0.9% sodium chloride, 750 mg/250 mL* (3 mg/mL), 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-6071-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable / IV Solution
- Hazard
- sterility-failure
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (15)
- Lot # 37-884161
- Exp 05/03/2023
- 37-885995
- 37-885997
- Exp 05/10/2023
- 37-887729
- Exp 05/17/2023
- 37-889595
- Exp 05/24/2023
- 37-891272
- Exp 05/31/2023
- 37-892162
- Exp 06/05/2023
- 37-894716
- Exp 06/14/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27